No Benefit With Atezolizumab in BRCA1/2-Mutant or HRD Ovarian Cancer
Adding atezolizumab to standard treatment did not improve PFS in patients with advanced ovarian cancer and BRCA1/2 mutations or HRD.
All articles by Julie Ehlers
Testing for ESR1 Mutations Recommended in HR+, HER2- Metastatic Breast Cancer
Routine testing for ESR1 mutations should occur upon recurrence or progression of HR+, HER2- metastatic breast cancer, a guideline suggests.
Belantamab Mafodotin Deemed Safe, Effective in Real-World MM Population
Belantamab mafodotin has shown clinical activity and a manageable safety profile in a real-world population of patients with relapsed/refractory multiple myeloma.
New Documentation Tool Improves Telephone Triage in Oncology Pain Management
A new pain assessment documentation tool is helping nurses in an ambulatory clinic better manage telephone triage in oncology care.
New Scale Quantifies Workload, Increases Productivity of Oncology Nurse Navigators
Study results show a new productivity scale measures the workloads of oncology nurse navigators and assists in increasing their productivity.
Educational Intervention Increases Nurses’ Knowledge of Cytokine Release Syndrome
A new pain assessment documentation tool is helping nurses in an ambulatory clinic better manage telephone triage in oncology care.
Adding Ipilimumab to Nivolumab Provides No Benefit in Recurrent or Metastatic HNSCC
Adding ipilimumab to treatment with nivolumab does not improve response or survival outcomes in recurrent/metastatic HNSCC, a phase 2 trial suggests.
Pediatric Cancer Survivors Have 4-Fold Higher Risk of Death 40 Years After Diagnosis
From 15 to 40 years after diagnosis, pediatric cancer survivors have a roughly 4-fold higher risk of death than the general population, a study suggests.
Avelumab Plus Cabozantinib Appears Safe, Active in Metastatic Clear Cell RCC
Avelumab plus cabozantinib has shown preliminary clinical activity and an acceptable safety profile in metastatic clear cell RCC, according to researchers.
- Loading...
Loading...
Next post in Kidney Cancer
Loading... 
Loading...